Ensysce Biosciences

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse and overdose while providing relief for those with severe pain, today announced management's participation in the 34th Annual Roth Conference being held March 13-15, 2022 at the Ritz Carlton, Laguna Niguel in Dana Point, California.

Ensysce Biosciences Announces Participation in the 34th Annual Roth Conference

SAN DIEGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse and overdose while providing relief for those with severe pain, today announced that Lee Rauch has been appointed to the Company's board of directors.

Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors

SAN DIEGO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with two novel technology platforms designed to provide relief for those suffering with severe pain while protecting against abuse and overdose, announced today the Company has engaged international investor relations specialists MZ Group (“MZ”) to lead a comprehensive strategic investor relations and financial communications program across all key markets.

Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program

SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, today reminded stockholders to vote at the upcoming special meeting of stockholders to be held on January 26, 2022 at 12:00 pm ET. This meeting will be held virtually using the following weblink https://agm.issuerdirect.com/ensc, for the following purposes:

Ensysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting

American Virtual Cloud Technologies

Insignia Systems

Reliance Global Group

Petros Pharmaceuticals

These five top short squeeze stocks are among the top speculative plays investors and traders are watching in today's market. The post Short Squeeze Stocks: ISIG, RELI and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.

Short Squeeze Stocks: ISIG, RELI and 3 Others Experts Think Are Ready to Pop

Potential short squeeze plays gained steam in 2021 with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch: Insignia Systems, American Virtual Cloud Top List Again, Reliance Global Rejoins

BE Study of PF614 Provides Critical Step toward FDA Approval BE Study of PF614 Provides Critical Step toward FDA Approval

Ensysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel “TAAP” Opioid

The stock price of Ensysce Biosciences Inc (NASDAQ: ENSC) increased by 18.16% in the most recent trading session. This is why it happened.

Ensysce Biosciences Stock (ENSC): Why The Price Jumped

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, today announced management's participation in the H.C. Wainwright BIOCONNECT Conference being held virtually January 10-13, 2022.

Ensysce Biosciences Announces Participation in the H.C. Wainwright BIOCONNECT Conference

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technologies that may provide new hope for those in severe pain, today announced that it has successfully completed Part A of the previously announced clinical study PF614-102, “A Phase 1b, Randomized, 2-Part Single-Center Study to Evaluate the Pharmacokinetics (PK) and Safety of Multiple-Ascending Oral Doses (MAD) of PF614 and the Food Effect and Bioavailability/Bioequivalence (BE) of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects,” conducted by Matthew Johnston, MD, PRA Health Sciences, Salt Lake City, Utah.

Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614

Energy Focus

SeaChange International

Siyata Mobile Inc.

As the new year kicks off, investors are looking forward to another positive year in the markets. And interest in short squeeze stocks has not waned.

Short Squeeze Stocks: ISIG, AVCT and 5 Others Experts Think Are Ready to Pop

Farmmi

Qualigen Therapeutics

Here are three penny stocks to watch right now The post Best Penny Stocks To Buy This Week? 3 For Your Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy This Week? 3 For Your Watch List

Inspira Technologies Oxy BHN Ltd

OPKO Health

Selecta Biosciences

4 penny stocks with bullish price targets & buy ratings from analysts. The post 4 Penny Stocks Analysts Say To Buy Now & Targets Up To 117% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks Analysts Say To Buy Now & Targets Up To 117%

Ensysce Biosciences is using its proprietary Trypsin-Activated Abuse Protection and Multi-Pill Abuse Resistance to develop tamper-proof, powerful opioids. Phase 1b study is ongoing for the Company's lead programs.

Ensysce Biosciences: Developing New Class Of Tamper-Proof Powerful Opioids

SAN DIEGO, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, today announced that the first patients have been enrolled in the Phase 1 study of PF614-MPARTM, the first product utilizing the Company's MPARTM platform designed to reduce opioid overdose.

Ensysce Biosciences Announces First Patients Enrolled in Phase 1 Study of PF614-MPAR™, its unique technology platform to provide opioid overdose protection

Arbutus Biopharma

Genius Brands

Vyne Therapeutics

Are these Reddit penny stocks on your watchlist right now? The post 4 Penny Stocks That Are Trending on Reddit Right Now and Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks That Are Trending on Reddit Right Now and Why

Ensysce Biosciences (ENSC) stock is in the news today as retail traders take interest in the company with plenty of chatter on social media. The post ENSC Stock Alert: What Investors Are Saying About Ensysce Biosciences as Shares Soar Today appeared first on InvestorPlace.

ENSC Stock Alert: What Investors Are Saying About Ensysce Biosciences as Shares Soar Today

The stock price of Ensysce Biosciences, Inc. (NASDAQ:ENSC) increased by over 85% pre-market today. This is why it happened.

Ensysce Biosciences Stock (ENSC): Why The Price Increased Today

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technologies that may provide new hope for those in severe pain, today announced the completion of a positive safety review and enrollment of the last cohort of subjects at the highest dose level in the Company's second study of its Trypsin Activated Abuse Protected (TAAP) Opioid, PF614.

Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today reported financial results for the third quarter of 2021 and recent corporate updates.

Ensysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, announced today that it has completed its previously announced private placement under a securities purchase agreement with institutional investors (“Investors”) for senior secured convertible notes (the “Notes”) and warrants exercisable for Ensysce common stock (the “Warrants”) for an aggregate investment of $15 million. The final funding by the Investors of $10 million, prior to fees and offering expenses, occurred on November 5, 2021.

Ensysce Biosciences Announces Completion of $15 Million Convertible Note Financing

SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, has appointed Linda Pestano, PhD, Chief Development Officer effective October 15, 2021.

Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, announced today that it has entered into a securities purchase agreement with institutional investors (“Investors”) in the form of senior secured convertible notes (the “Notes”) and warrants exercisable for Ensysce common stock (the “Warrants”) in a private placement for an aggregate investment of $15 million. An initial funding by the Investors occurred on September 24, 2021, for $5 million prior to fees and offering expenses.

Ensysce Biosciences Announces $15 Million Convertible Note Financing

Company Commences Second Study of Trypsin Activated Abuse Protected (TAAP) Opioid, PF614, on September 7, 2021 Company Commences Second Study of Trypsin Activated Abuse Protected (TAAP) Opioid, PF614, on September 7, 2021

Ensysce Biosciences Announces Treatment of First Cohort for Subjects in Clinical Study of its Next Generation Opioid, PF614

SAN DIEGO, CA / ACCESSWIRE / August 31, 2021 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, is scheduled to participate at the following industry and financial conferences during September 2021: 10th Annual Gateway Conference Date and Time: Held virtually on September 8-9, 2021 Description: Ensysce CEO Dr. Lynn Kirkpatrick is scheduled to present on Wednesday, September 8 at 1:00 p.m. Pacific Time, with one-on-one meetings to be held throughout the conference.

News for Ensysce Biosciences Stock (ENSC)